The manuscript on COVID-19 in patients with autoimmune liver diseases, based on data from the R-LIVER COVID-19 registry and in cooperation with the EASL and international COVID-19 registry, was recently accepted for publication by the Journal of Hepatology. [read more]

Gene transfer to the liver may be used to treat specific liver diseases, but can also induce hepatic protein production to treat conditions that do not affect the liver itself. While gene therapy is still in its infancy, preclinical and clinical trials have already shown promising results in several diseases. For instance, in Hemophilia A, an X-linked bleeding disorder due to deficiencies in coagulation factor VIII, multiple clinical trials with AAV-vector liver-directed gene therapy have reported promising results in restoring therapeutically relevant FVIII levels with sustained production for years (1).  [read more]

There are insufficient population-level data on the effects of primary sclerosing cholangitis (PSC) in patients with inflammatory bowel disease (IBD).  [read more]

Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for 15% of all primary liver cancers and 3% of gastrointestinal malignancies. [read more]

We are very pleased to share the link to our Journal of Hepatology paper on 2nd and 3rd line therapy of Autoimmune Hepatitis. [read more]

The Alpha1-Liver Team from Aachen, Germany, which coordinates the European study group for alpha1-antitrypsin deficiency-related liver disease, has published the latest results on liver involvement in mild alpha1-antitrypsin deficiency in the renowned journal, Gastroenterology. This work appears a year after the contribution that focused on the liver phenotype in severe alpha1-antitrypsin deficiency and was also published in Gastroenterology. [read more]